Medigen Vaccine Gross Profit vs. Price To Book

6547 Stock  TWD 34.35  1.10  3.10%   
Based on the measurements of profitability obtained from Medigen Vaccine's financial statements, Medigen Vaccine Biologics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Medigen Vaccine's ability to earn profits and add value for shareholders.
For Medigen Vaccine profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Medigen Vaccine to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Medigen Vaccine Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Medigen Vaccine's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Medigen Vaccine Biologics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Medigen Vaccine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medigen Vaccine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medigen Vaccine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Medigen Vaccine Biologics Price To Book vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Medigen Vaccine's current stock value. Our valuation model uses many indicators to compare Medigen Vaccine value to that of its competitors to determine the firm's financial worth.
Medigen Vaccine Biologics is number one stock in gross profit category among its peers. It also is number one stock in price to book category among its peers . The ratio of Gross Profit to Price To Book for Medigen Vaccine Biologics is about  489,007,149 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medigen Vaccine's earnings, one of the primary drivers of an investment's value.

Medigen Price To Book vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Medigen Vaccine

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
2.31 B
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Medigen Vaccine

P/B

 = 

MV Per Share

BV Per Share

 = 
4.71 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Medigen Price To Book Comparison

Medigen Vaccine is currently under evaluation in price to book category among its peers.

Medigen Vaccine Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Medigen Vaccine, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Medigen Vaccine will eventually generate negative long term returns. The profitability progress is the general direction of Medigen Vaccine's change in net profit over the period of time. It can combine multiple indicators of Medigen Vaccine, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp. MEDIGEN VACCINE operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.

Medigen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Medigen Vaccine. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Medigen Vaccine position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Medigen Vaccine's important profitability drivers and their relationship over time.

Use Medigen Vaccine in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medigen Vaccine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Vaccine will appreciate offsetting losses from the drop in the long position's value.

Medigen Vaccine Pair Trading

Medigen Vaccine Biologics Pair Trading Analysis

The ability to find closely correlated positions to Medigen Vaccine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medigen Vaccine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medigen Vaccine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medigen Vaccine Biologics to buy it.
The correlation of Medigen Vaccine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medigen Vaccine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medigen Vaccine Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medigen Vaccine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Medigen Vaccine position

In addition to having Medigen Vaccine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Furniture Thematic Idea Now

Furniture
Furniture Theme
Companies producing and selling home and office furniture. The Furniture theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Medigen Stock Analysis

When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.